Twice versus thrice weekly hemodialysis: A systematic review. Issue 4 (12th September 2022)

• Record Type: Journal Article
• Authors: Moorman, Danielle; Pilkey, Nathan G.; Goss, Chloe J.; Holden, Rachel M.; Welihinda, Hasitha; Kennedy, Claire; Halliday, Sandra M.; White, Christine A.
• Is Part Of: Hemodialysis international. Volume 26:Issue 4(2022)
• Page Start: 461
• Page End: 479
• Publication Date: 2022-09-12
• Subjects: hemodialysis frequency -- residual kidney function -- survival -- systematic review; Hemodialysis -- Periodicals; Renal Dialysis -- Periodicals; Renal Dialysis -- Congresses; Hemodialysis, Home -- Congresses; 617.461059
• DOI: 10.1111/hdi.13045
• Languages: English
• ISSNs: 1492-7535

Abstract

Abstract: Introduction: Thrice weekly hemodialysis (HD) is currently the norm in high income countries but there is mounting interest in twice weekly HD in certain settings. We performed this systematic review to summarize the available evidence comparing twice to thrice weekly HD. Methods: A systematic literature search was performed in Ovid MEDLINE, Ovid Embase, and the Cochrane Central Register of Controlled Trials to identify cohort and randomized controlled trials evaluating outcomes of twice versus thrice weekly HD. The bibliographies of identified studies were hand searched to find any additional studies. Risk of bias was assessed using the Newcastle–Ottawa scale for observational studies. Findings: No randomized controlled trials and 21 cohort studies were identified. Overall study quality was modest with high risk of selection bias and inadequate controlling for confounders. The most commonly evaluated outcome measures were survival and residual kidney function. No studies assessed quality of life. Study results were variable and there was no clear signal for overwhelming risk or benefit of twice versus thrice weekly HD with the exception of residual kidney function which consistently showed slower decline in the twice weekly group. Discussion: There is a paucity of high quality data comparing the risks and benefits of twice vs thrice weekly HD. Randomized controlled trial evidence is required to inform clinicians and HD prescription guidelines.